A Form 144 notice of proposed sale of securities was filed on November 2, 2026, by David M. Wright, identified as a member of the immediate family of an officer of Itron, Inc., covering 410 shares of Itron common stock with an aggregate market …
A Form 144 notice of proposed sale was filed on November 2, 2026, disclosing that 410 shares of Itron, Inc. common stock are to be sold from the account of Alexander P. Wright, son of David M. Wright, an officer of the company.
Brunswick Corp director Nancy E. Cooper filed a Form 144 notice of proposed sale of 216 shares of Brunswick common stock, with an approximate sale date of November 2, 2026.
Palo Alto Networks, Inc. officer William D Jenkins Jr. filed a Form 144 notice on November 2, 2026, disclosing a proposed sale of 18,222 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services.
Director Sarah A. Slusser of Nextpower Inc. filed a Form 4 on November 2, 2026, reporting the acquisition of 2,547 restricted stock units of common stock on November 1, 2026, at a price of $0.
Director Sarah A. Slusser filed a Form 3 Initial Statement of Beneficial Ownership with the SEC on November 2, 2026, reporting no securities beneficially owned as of the event date of November 1, 2026, at Nextpower Inc. (NASDAQ:NXT).
Jazz Pharmaceuticals Plc officer Bruce C. Cozadd filed a Form 144 notice on November 2, 2026, proposing to sell 6,000 shares of Jazz Pharmaceuticals common stock on NASDAQ with an aggregate market value of $1,295,040.
FTAI Aviation Ltd. filed a Form 8-K on November 2, 2026, disclosing that its subsidiary FTAI Aviation Investors LLC priced a private offering of $1.0 billion aggregate principal amount of 7.125% senior notes due 2034.
BWX Technologies, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the Securities and Exchange Commission on November 2, 2026, disclosing condensed consolidated financial statements and related management discussion for the three and nine months ended September 30, 2026.
Neurocrine Biosciences, Inc. filed its quarterly report on Form 10-Q with the SEC on November 2, 2026, covering the three and nine months ended September 30, 2026, and reporting net income of $548.8 million for the nine-month period.